<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.rbej.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Reproductive Biology and Endocrinology - Most accessed articles</title>
        <link>http://www.rbej.com</link>
        <description>The most accessed research articles published by Reproductive Biology and Endocrinology</description>
        <dc:date>2012-04-27T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.rbej.com/content/1/1/110" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/10/1/14" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/10/1/7" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/7/1/120" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/9/1/67" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/10/1/26" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/10/1/35" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/8/1/141" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/8/1/24" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/3/1/28" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.rbej.com/content/1/1/110">
        <title>Assessment of fetal intracranial pathologies first demonstrated late in pregnancy: cell proliferation disorders</title>
        <description>A considerable number of central nervous system pathologies remain undiagnosed during the first two trimesters of pregnancy. This group of disorders includes anomalies of brain proliferation, migration and cortical organization. Due to the fact that a detailed ultrasound examination of the fetal brain is usually not performed during the third trimester the diagnosis of these disorders is usually only made in families with a previously affected child or in many cases be mere chance. In this article we review the feasibility of prenatal diagnosis of disorders of brain proliferation: microcephaly, macrocephaly, hemimegalencephaly and neoplastic and non-neoplastic abnormal cell types. We discuss the differential diagnosis and offer a stepwise approach to the diagnosis of the more common disorders.</description>
        <link>http://www.rbej.com/content/1/1/110</link>
                <dc:creator>Gustavo Malinger</dc:creator>
                <dc:creator>Dorit Lev</dc:creator>
                <dc:creator>Tally Lerman-Sagie</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2003, null:110</dc:source>
        <dc:date>2003-11-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-1-110</dc:identifier>
                                <prism:require>/content/figures/1477-7827-1-110-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>110</prism:startingPage>
        <prism:publicationDate>2003-11-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/10/1/14">
        <title>Resveratrol promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: an implicative role of SIRT1 in the ovary</title>
        <description>Background:
Resveratrol is a natural polyphenolic compound known for its beneficial effects on energy homeostasis, and it also has multiple properties, including anti-oxidant, anti-inflammatory, and anti-tumor activities. Recently, silent information regulator genes (Sirtuins) have been identified as targets of resveratrol. Sirtuin 1 (SIRT1), originally found as an NAD+-dependent histone deacetylase, is a principal modulator of pathways downstream of calorie restriction, and the activation of SIRT1 ameliorates glucose homeostasis and insulin sensitivity. To date, the presence and physiological role of SIRT1 in the ovary are not known. Here we found that SIRT1 was localized in granulosa cells of the human ovary.
Methods:
The physiological roles of resveratrol and SIRT1 in the ovary were analyzed. Immunohistochemistry was performed to localize the SIRT1 expression. SIRT1 protein expression of cultured cells and luteinized human granulosa cells was investigated by Western blot. Rat granulosa cells were obtained from diethylstilbestrol treated rats. The cells were treated with increasing doses of resveratrol, and subsequently harvested to determine mRNA levels and protein levels. Cell viability was tested by MTS assay. Cellular apoptosis was analyzed by caspase 3/7 activity test and Hoechst 33342 staining.
Results:
SIRT1 protein was expressed in the human ovarian tissues and human luteinized granulosa cells. We demonstrated that resveratrol exhibited a potent concentration-dependent inhibition of rat granulosa cells viability. However, resveratrol-induced inhibition of rat granulosa cells viability is independent of apoptosis signal. Resveratrol increased mRNA levels of SIRT1, LH receptor, StAR, and P450 aromatase, while mRNA levels of FSH receptor remained unchanged. Western blot analysis was consistent with the results of quantitative real-time RT-PCR assay. In addition, progesterone secretion was induced by the treatment of resveratrol.
Conclusions:
These results suggest a novel mechanism that resveratrol could enhance progesterone secretion and expression of luteinization-related genes in the ovary, and thus provide important implications to understand the mechanism of luteal phase deficiency.</description>
        <link>http://www.rbej.com/content/10/1/14</link>
                <dc:creator>Yoshihiro Morita</dc:creator>
                <dc:creator>Osamu Wada-Hiraike</dc:creator>
                <dc:creator>Tetsu Yano</dc:creator>
                <dc:creator>Akira Shirane</dc:creator>
                <dc:creator>Mana Hirano</dc:creator>
                <dc:creator>Haruko Hiraike</dc:creator>
                <dc:creator>Satoshi Koyama</dc:creator>
                <dc:creator>Hajime Oishi</dc:creator>
                <dc:creator>Osamu Yoshino</dc:creator>
                <dc:creator>Yuichiro Miyamoto</dc:creator>
                <dc:creator>Kenbun Sone</dc:creator>
                <dc:creator>Katsutoshi Oda</dc:creator>
                <dc:creator>Shunsuke Nakagawa</dc:creator>
                <dc:creator>Kazuyoshi Tsutsui</dc:creator>
                <dc:creator>Yuji Taketani</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2012, null:14</dc:source>
        <dc:date>2012-02-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-10-14</dc:identifier>
                                <prism:require>/content/figures/1477-7827-10-14-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2012-02-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/10/1/7">
        <title>Therapeutic ultrasound as a potential male contraceptive: power, frequency and temperature required to deplete rat testes of meiotic cells and epididymides of sperm determined using a commercially available system</title>
        <description>Background:
Studies published in the 1970s by Mostafa S. Fahim and colleagues showed that a short treatment with ultrasound caused the depletion of germ cells and infertility. The goal of the current study was to determine if a commercially available therapeutic ultrasound generator and transducer could be used as the basis for a male contraceptive.
Methods:
Sprague-Dawley rats were anesthetized and their testes were treated with 1 MHz or 3 MHz ultrasound while varying power, duration and temperature of treatment.
Results:
We found that 3 MHz ultrasound delivered with 2.2 Watt per square cm power for fifteen minutes was necessary to deplete spermatocytes and spermatids from the testis and that this treatment significantly reduced epididymal sperm reserves. 3 MHz ultrasound treatment reduced total epididymal sperm count 10-fold lower than the wet-heat control and decreased motile sperm counts 1,000-fold lower than wet-heat alone. The current treatment regimen provided nominally more energy to the treatment chamber than Fahim&apos;s originally reported conditions of 1 MHz ultrasound delivered at 1 Watt per square cm for ten minutes. However, the true spatial average intensity, effective radiating area and power output of the transducers used by Fahim were not reported, making a direct comparison impossible. We found that germ cell depletion was most uniform and effective when we rotated the therapeutic transducer to mitigate non-uniformity of the beam field. The lowest sperm count was achieved when the coupling medium (3% saline) was held at 37 degrees C and two consecutive 15-minute treatments of 3 MHz ultrasound at 2.2 Watt per square cm were separated by 2 days.
Conclusions:
The non-invasive nature of ultrasound and its efficacy in reducing sperm count make therapeutic ultrasound a promising candidate for a male contraceptive. However, further studies must be conducted to confirm its efficacy in providing a contraceptive effect, to test the result of repeated use, to verify that the contraceptive effect is reversible and to demonstrate that there are no detrimental, long-term effects from using ultrasound as a method of male contraception.</description>
        <link>http://www.rbej.com/content/10/1/7</link>
                <dc:creator>James Tsuruta</dc:creator>
                <dc:creator>Paul Dayton</dc:creator>
                <dc:creator>Caterina Gallippi</dc:creator>
                <dc:creator>Michael O'Rand</dc:creator>
                <dc:creator>Michael Streicker</dc:creator>
                <dc:creator>Ryan Gessner</dc:creator>
                <dc:creator>Thomas Gregory</dc:creator>
                <dc:creator>Erick Silva</dc:creator>
                <dc:creator>Katherine Hamil</dc:creator>
                <dc:creator>Glenda Moser</dc:creator>
                <dc:creator>David Sokal</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2012, null:7</dc:source>
        <dc:date>2012-01-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-10-7</dc:identifier>
                            <dc:title>Ultrasound as a male contraceptive</dc:title>
                            <dc:description>Ultrasound has been used in rats to produce a Sperm Count Index of zero. The non-invasive and reversible nature of this treatment makes it a promising candidate for a male contraceptive.</dc:description>
                <prism:require>/content/figures/1477-7827-10-7-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2012-01-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/7/1/120">
        <title>The role and molecular mechanism of D-aspartic acid in the release and synthesis of LH and testosterone in human and rats
</title>
        <description>Background:
D-aspartic acid is an amino acid present in neuroendocrine tissues of invertebrates and vertebrates, including rats and humans. Here we investigated the effect of this amino acid on the release of LH and testosterone in the serum of humans and rats. Furthermore, we investigated the role of D-aspartate in the synthesis of LH and testosterone in the pituitary and testes of rats, and the molecular mechanisms by which this amino acid triggers its action.
Methods:
For humans: A group of 23 men were given a daily dose of D-aspartate (DADAVIT&#174;) for 12 days, whereas another group of 20 men were given a placebo. For rats: A group of 10 rats drank a solution of either 20 mM D-aspartate or a placebo for 12 days. Then LH and testosterone accumulation was determined in the serum and D-aspartate accumulation in tissues. The effects of D-aspartate on the synthesis of LH and testosterone were gauged on isolated rat pituitary and Leydig cells. Tissues were incubated with D-aspartate, and then the concentration (synthesis) of LH and cGMP in the pituitary and of testosterone and cAMP in the Leydig cells was determined.
Results:
In humans and rats, sodium D-aspartate induces an enhancement of LH and testosterone release. In the rat pituitary, sodium D-aspartate increases the release and synthesis of LH through the involvement of cGMP as a second messenger, whereas in rat testis Leydig cells, it increases the synthesis and release of testosterone and cAMP is implicated as second messenger. In the pituitary and in testes D-Asp is synthesized by a D-aspartate racemase which convert L-Asp into D-Asp. The pituitary and testes possesses a high capacity to trapping circulating D-Asp from hexogen or endogen sources.
Conclusion:
D-aspartic acid is a physiological amino acid occurring principally in the pituitary gland and testes and has a role in the regulation of the release and synthesis of LH and testosterone in humans and rats.</description>
        <link>http://www.rbej.com/content/7/1/120</link>
                <dc:creator>Enza Topo</dc:creator>
                <dc:creator>Andrea Soricelli</dc:creator>
                <dc:creator>Antimo D'Aniello</dc:creator>
                <dc:creator>Salvatore Ronsini</dc:creator>
                <dc:creator>Gemma D'Aniello</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2009, null:120</dc:source>
        <dc:date>2009-10-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-7-120</dc:identifier>
                                <prism:require>/content/figures/1477-7827-7-120-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>120</prism:startingPage>
        <prism:publicationDate>2009-10-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/9/1/67">
        <title>Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR) </title>
        <description>Background:
With infertility populations in the developed world rapidly aging, treatment of diminished ovarian reserve (DOR) assumes increasing clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy chances with DOR, and is now utilized by approximately one third of all IVF centers world-wide. Increasing DHEA utilization and publication of a first prospectively randomized trial now warrants a systematic review.
Methods:
PubMed, Cochrane and Ovid Medline were searched between 1995 and 2010 under the following strategy: [&lt;dehydroepiandrosterone or DHEA or androgens or testosterone &gt; and &lt;ovarian reserve or diminished ovarian reserve or ovarian function &gt;]. Bibliographies of relevant publications were further explored for additional relevant citations. Since only one randomized study has been published, publications, independent of evidence levels and quality assessment, were reviewed.
Results:
Current best available evidence suggests that DHEA improves ovarian function, increases pregnancy chances and, by reducing aneuploidy, lowers miscarriage rates. DHEA over time also appears to objectively improve ovarian reserve. Recent animal data support androgens in promoting preantral follicle growth and reduction in follicle atresia.DiscussionImprovement of oocyte/embryo quality with DHEA supplementation potentially suggests a new concept of ovarian aging, where ovarian environments, but not oocytes themselves, age. DHEA may, thus, represent a first agent beneficially affecting aging ovarian environments. Others can be expected to follow.</description>
        <link>http://www.rbej.com/content/9/1/67</link>
                <dc:creator>Norbert Gleicher</dc:creator>
                <dc:creator>David Barad</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2011, null:67</dc:source>
        <dc:date>2011-05-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-9-67</dc:identifier>
                                <prism:require>/content/figures/1477-7827-9-67-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>67</prism:startingPage>
        <prism:publicationDate>2011-05-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/10/1/26">
        <title>GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET)</title>
        <description>Several protocols are actually available for in Vitro Fertilization and Embryo Transfer. The review summarizes the main differences and the clinic characteristics of the protocols in use with GnRH agonists and GnRH antagonists by emphasizing the major outcomes and hormonal changes associated with each protocol. The majority of randomized clinical trials clearly shows that in &quot;in Vitro&quot; Fertilization and Embryo Transfer, the combination of exogenous Gonadotropin plus a Gonadotropin Releasing Hormone (GnRH) agonist, which is able to suppress pituitary FSH and LH secretion, is associated with increased pregnancy rate as compared with the use of gonadotropins without a GnRH agonist. Protocols with GnRH antagonists are effective in preventing a premature rise of LH and induce a shorter and more cost-effective ovarian stimulation compared to the long agonist protocol. However, a different synchronization of follicular recruitment and growth occurs with GnRH agonists than with GnRH antagonists. Future developments have to be focused on timing of the administration of GnRH antagonists, by giving a great attention to new strategies of stimulation in patients in which radio-chemotherapy cycles are needed.</description>
        <link>http://www.rbej.com/content/10/1/26</link>
                <dc:creator>Raffaella Depalo</dc:creator>
                <dc:creator>K Jayakrishnan</dc:creator>
                <dc:creator>Gabriella Garruti</dc:creator>
                <dc:creator>Ilaria Totaro</dc:creator>
                <dc:creator>Mariantonietta Panzarino</dc:creator>
                <dc:creator>Francesco Giorgino</dc:creator>
                <dc:creator>Luigi Selvaggi</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2012, null:26</dc:source>
        <dc:date>2012-04-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-10-26</dc:identifier>
                                <prism:require>/content/figures/1477-7827-10-26-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>26</prism:startingPage>
        <prism:publicationDate>2012-04-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/10/1/35">
        <title>Minimal ovarian stimulation combined with elective single embryo transfer policy: age-specific results of a large, single-centre, Japanese cohort</title>
        <description>Background:
the two main complications associated with the use of assisted reproduction techniques, ovarian hyperstimulation syndrome and multiple pregnancies, could be eliminated by milder ovarian stimulation protocols and the increased use of a single embryo transfer (SET) policy. A retrospective, cohort study was performed in private infertility centre to evaluate the embryological and clinical results of a large exclusively SET program according to patient age (lower or equal 29, 30-34, 35-39, 40-44 and equal or higher 45 years).Materials: A total of 7,244 infertile patients have undergone 20,244 cycles with a clomiphene-based minimal stimulation or natural cycle IVF protocol during 2008. Following oocyte retrieval, fertilization and embryo culture a total of 10,401 fresh or frozen single embryo transfer procedures were performed involving cleavage-stage embryos or blastocysts.
Results:
Successful oocyte retrieval rate (78.0%) showed no age-dependent decrease until 45 years. Fertilization (80.3%) and cleavage (91.1%) rates were not significantly different between age groups. Blastocyst formation (70.1% to 22.8%) and overall live birth rates (35.9 % to 2%) showed an age-dependent decrease. Frozen-thawed blastocyst transfer cycles gave the highest chance of live birth per embryo transfer (41.3% to 6.1%).
Conclusions:
High fertilization and cleavage rates were obtained regardless of age whereas blastocyst formation and live birth rates showed an age-dependent decrease. An elective single embryo transfer program based on a minimal ovarian stimulation protocol yields acceptable live birth rates per embryo transfer in infertile patients up until their mid-forties. However in very advanced age patients (equal or higher 45 years old) success rates fall below 1%.</description>
        <link>http://www.rbej.com/content/10/1/35</link>
                <dc:creator>Keiichi Kato</dc:creator>
                <dc:creator>Yuji Takehara</dc:creator>
                <dc:creator>Tomoya Segawa</dc:creator>
                <dc:creator>Satoshi Kawachiya</dc:creator>
                <dc:creator>Takashi Okuno</dc:creator>
                <dc:creator>Tamotsu Kobayashi</dc:creator>
                <dc:creator>Daniel Bodri</dc:creator>
                <dc:creator>Osamu Kato</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2012, null:35</dc:source>
        <dc:date>2012-04-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-10-35</dc:identifier>
                                <prism:require>/content/figures/1477-7827-10-35-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>35</prism:startingPage>
        <prism:publicationDate>2012-04-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/8/1/141">
        <title>The complexity of premenstrual dysphoric disorder - risk factors in the population of Polish women</title>
        <description>Background:
Premenstrual dysphoric disorder has multiple determinants in the biological, psychological and socio-cultural domains. The aim of the study was to evaluate the risk factors for premenstrual dysphoric disorder in Polish women, considering their reproductive history, socio-economic factors, as well as lifestyle and health-related factors.
Methods:
2,500 females, aged 18 to 45, from the Upper Silesian region of Poland were eligible for the prospective population study. The final study sample was 1,540 individuals. The research was based on a questionnaire containing socio-economic status, general health, lifestyle, medical and reproductive history, premenstrual symptoms based on the American Psychiatric Association&apos;s criteria for diagnosing premenstrual dysphoric disorder, and patient prospective daily ratings of symptoms. The Statistica 8.0 computer software was used for statistical analysis. The value of p &lt; 0.05 was adopted as the level of statistical significance.
Results:
The mean age of the studied population was 31.9 +/- 7.3 years. The majority of the studied women were married (57.9%), lived in large cities (42.0%) and had tertiary education (43.2%). The results of the study indicated that the prevalence of premenstrual dysphoric disorder was 2.1%. The final statistical analysis revealed that only tertiary education decreased the risk of premenstrual dysphoric disorder (OR = 0.08; p &lt; 0.05).
Conclusions:
Our research showed that women with tertiary education are less vulnerable to premenstrual dysphoric disorder than women with a lower level of education. Reproductive and lifestyle factors seem to be play a lesser role.</description>
        <link>http://www.rbej.com/content/8/1/141</link>
                <dc:creator>Violetta Skrzypulec-Plinta</dc:creator>
                <dc:creator>Agnieszka Drosdzol</dc:creator>
                <dc:creator>Krzysztof Nowosielski</dc:creator>
                <dc:creator>Ryszard Plinta</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2010, null:141</dc:source>
        <dc:date>2010-11-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-8-141</dc:identifier>
                                <prism:require>/content/figures/1477-7827-8-141-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>141</prism:startingPage>
        <prism:publicationDate>2010-11-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/8/1/24">
        <title>A massive ovarian mucinous cystadenoma: a case report</title>
        <description>ObjectivesTo report the occurrence of a rare case of a huge benign ovarian tumour (mucinous cystadenoma) in Jazan city, Saudi Arabia.PatientsOur reported case was a middle-aged Saudi woman presented with marked abdominal distension and discomfort at the gynaecology clinic of Jazan General Hospital, Jazan city, Saudi Arabia.
Methods:
The data were collected by history-taking, clinical examination, laboratory investigations, transabdominal ultrasonographic examination, and by histo-pathological study of the excised surgical specimen.
Results:
The case was reported as a rare massive ovarian mucinous cystadenoma.
Conclusions:
This case report emphasizes the significance of thorough evaluation of all women presented with vague abdominal pains. Although the condition is extremely rare, it is a potentially dangerous in its massive form if not timely diagnosed and managed properly. With the increasing awareness of such conditions, more and more cases could be detected and reported early.</description>
        <link>http://www.rbej.com/content/8/1/24</link>
                <dc:creator>Remah Kamel</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2010, null:24</dc:source>
        <dc:date>2010-03-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-8-24</dc:identifier>
                                <prism:require>/content/figures/1477-7827-8-24-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>24</prism:startingPage>
        <prism:publicationDate>2010-03-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/3/1/28">
        <title>Role of oxidative stress in female reproduction</title>
        <description>In a healthy body, ROS (reactive oxygen species) and antioxidants remain in balance. When the balance is disrupted towards an overabundance of ROS, oxidative stress (OS) occurs. OS influences the entire reproductive lifespan of a woman and even thereafter (i.e. menopause). OS results from an imbalance between prooxidants (free radical species) and the body&apos;s scavenging ability (antioxidants). ROS are a double-edged sword &#8211; they serve as key signal molecules in physiological processes but also have a role in pathological processes involving the female reproductive tract. ROS affect multiple physiological processes from oocyte maturation to fertilization, embryo development and pregnancy. It has been suggested that OS modulates the age-related decline in fertility. It plays a role during pregnancy and normal parturition and in initiation of preterm labor. Most ovarian cancers appear in the surface epithelium, and repetitive ovulation has been thought to be a causative factor. Ovulation-induced oxidative base damage and damage to DNA of the ovarian epithelium can be prevented by antioxidants. There is growing literature on the effects of OS in female reproduction with involvement in the pathophsiology of preeclampsia, hydatidiform mole, free radical-induced birth defects and other situations such as abortions. Numerous studies have shown that OS plays a role in the pathoysiology of infertility and assisted fertility. There is some evidence of its role in endometriosis, tubal and peritoneal factor infertility and unexplained infertility. This article reviews the role OS plays in normal cycling ovaries, follicular development and cyclical endometrial changes. It also discusses OS-related female infertility and how it influences the outcomes of assisted reproductive techniques. The review comprehensively explores the literature for evidence of the role of oxidative stress in conditions such as abortions, preeclampsia, hydatidiform mole, fetal embryopathies, preterm labour and preeclampsia and gestational diabetes. The review also addresses the growing literature on the role of nitric oxide species in female reproduction. The involvement of nitric oxide species in regulation of endometrial and ovarian function, etiopathogenesis of endometriosis, and maintenance of uterine quiescence, initiation of labour and ripening of cervix at parturition is discussed. Complex interplay between cytokines and oxidative stress in the etiology of female reproductive disorders is discussed. Oxidant status of the cell modulates angiogenesis, which is critical for follicular growth, corpus luteum formation endometrial differentiation and embryonic growth is also highlighted in the review. Strategies to overcome oxidative stress and enhance fertility, both natural and assisted are delineated. Early interventions being investigated for prevention of preeclampsia are enumerated. Trials investigating combination intervention strategy of vitamin E and vitamin C supplementation in preventing preeclampsia are highlighted. Antioxidants are powerful and there are few trials investigating antioxidant supplementation in female reproduction. However, before clinicians recommend antioxidants, randomized controlled trials with sufficient power are necessary to prove the efficacy of antioxidant supplementation in disorders of female reproduction. Serial measurement of oxidative stress biomarkers in longitudinal studies may help delineate the etiology of some of the diosorders in female reproduction such as preeclampsia.</description>
        <link>http://www.rbej.com/content/3/1/28</link>
                <dc:creator>Ashok Agarwal</dc:creator>
                <dc:creator>Sajal Gupta</dc:creator>
                <dc:creator>Rakesh Sharma</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2005, null:28</dc:source>
        <dc:date>2005-07-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-3-28</dc:identifier>
                                <prism:require>/content/figures/1477-7827-3-28-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>28</prism:startingPage>
        <prism:publicationDate>2005-07-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

